
Sign up to save your podcasts
Or


This week on BioTech Nation, we explore new efforts in treating cancer with Dr. Sean Bohen, President and CEO of Olema Oncology. We discuss progress in treating breast cancer, particularly ER+/HER2- breast cancer, which accounts for 70% of diagnoses this year. They examine the biology behind these cancers and how Olema's lead compound, palazestrant, works to antagonize the estrogen receptor, halting cancer cell growth. They also touch on the ongoing Phase 3 trial, OPERA-01, and the potential for combining palazestrant with other treatments.
By Moira Gunn4.1
2929 ratings
This week on BioTech Nation, we explore new efforts in treating cancer with Dr. Sean Bohen, President and CEO of Olema Oncology. We discuss progress in treating breast cancer, particularly ER+/HER2- breast cancer, which accounts for 70% of diagnoses this year. They examine the biology behind these cancers and how Olema's lead compound, palazestrant, works to antagonize the estrogen receptor, halting cancer cell growth. They also touch on the ongoing Phase 3 trial, OPERA-01, and the potential for combining palazestrant with other treatments.

21,973 Listeners

43,962 Listeners

32,073 Listeners

30,782 Listeners

43,680 Listeners

708 Listeners

6,423 Listeners

30,225 Listeners

124 Listeners

321 Listeners

10,017 Listeners

34 Listeners

21 Listeners

50 Listeners

147 Listeners